2-Aminoindane

2-Aminoindane (2-AI) is a synthetic stimulant of the aminoindane chemical class — a family of bicyclic compounds structurally derived from indane, a molecule consisting of a cyclopentane ring fused to a benzene ring. The aminoindane class was originally developed in the 1990s as part of pharmaceutical research into safer non-neurotoxic stimulants, with 2-AI serving as the primary parent compound. Unlike amphetamine or methamphetamine, 2-aminoindane is generally believed to lack significant serotonin-releasing activity, which is associated with neurotoxic potential in fluorinated and substituted amphetamine analogs.

The subjective effects of 2-AI at typical doses are characterized as relatively mild compared to classical amphetamines — producing wakefulness, moderate focus enhancement, and gentle mood elevation without the cardiovascular intensity or compulsive redosing profile of methamphetamine or 4-FA. Community reports consistently describe it as a "subtle" stimulant, well-suited to low-intensity productivity tasks rather than recreational use, with a relatively clean headspace and modest side effect burden. Experience reports note that the onset is gradual and the duration moderate, typically 3–5 hours.

2-AI has attracted interest in the harm reduction community as a potential study aid given its purported non-neurotoxicity — the absence of the serotonergic releasing component that makes some fluorinated amphetamines potentially damaging with heavy use. However, this claim is based primarily on structural inference and animal studies; comprehensive human safety data remain unavailable. The substance is currently unscheduled in most jurisdictions, though some countries have implemented analog act coverage.